OPDUALAG NIVOLUMAB/RELATLIMAB) Trademark

Trademark Overview

On Friday, February 21, 2020, a trademark application was filed for OPDUALAG NIVOLUMAB/RELATLIMAB) with the United States Patent and Trademark Office. The USPTO has given the OPDUALAG NIVOLUMAB/RELATLIMAB) trademark a serial number of 88805781. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, October 30, 2023. This trademark is owned by Bristol-Myers Squibb Company. The OPDUALAG NIVOLUMAB/RELATLIMAB) trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of cancer, all of the foregoing comprising monoclonal antibodies

Health care services, namely, providing information to physicians, health care professionals and patients on the topic of health issues, health awareness and pharmaceuticals; Providing a website featuring educational information in the field of healthcare and pharmaceutical preparations; all of the foregoing involving monoclonal antibodies
opdualag nivolumab/relatlimab)

General Information

Serial Number88805781
Word MarkOPDUALAG NIVOLUMAB/RELATLIMAB)
Filing DateFriday, February 21, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, October 30, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, August 3, 2021

Trademark Statements

Description of MarkThe mark consists of the term "OPDUALAG" with a curved line over it and the term ("NIVOLUMAB/RELATLIMAB") below it.
Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of cancer, all of the foregoing comprising monoclonal antibodies
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and ServicesHealth care services, namely, providing information to physicians, health care professionals and patients on the topic of health issues, health awareness and pharmaceuticals; Providing a website featuring educational information in the field of healthcare and pharmaceutical preparations; all of the foregoing involving monoclonal antibodies
Disclaimer with Predetermined Text"NIVOLUMAB/RELATLIMAB"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 25, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, February 25, 2020
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543
Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events

Event DateEvent Description
Monday, October 30, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, October 30, 2023ABANDONMENT - NO USE STATEMENT FILED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, March 9, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, March 7, 2023SOU EXTENSION 3 GRANTED
Tuesday, March 7, 2023SOU EXTENSION 3 FILED
Tuesday, March 7, 2023SOU TEAS EXTENSION RECEIVED
Thursday, September 15, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, September 13, 2022SOU EXTENSION 2 GRANTED
Tuesday, September 13, 2022SOU EXTENSION 2 FILED
Tuesday, September 13, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, March 9, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 7, 2022SOU EXTENSION 1 GRANTED
Monday, March 7, 2022SOU EXTENSION 1 FILED
Monday, March 7, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, September 28, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, August 3, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 3, 2021PUBLISHED FOR OPPOSITION
Wednesday, July 14, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, June 30, 2021LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, June 30, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 23, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, June 23, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 22, 2021ASSIGNED TO LIE
Friday, April 9, 2021NOTICE OF REVIVAL - E-MAILED
Thursday, April 8, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 8, 2021PETITION TO REVIVE-GRANTED
Thursday, April 8, 2021TEAS PETITION TO REVIVE RECEIVED
Tuesday, September 22, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, September 22, 2020NON-FINAL ACTION E-MAILED
Tuesday, September 22, 2020NON-FINAL ACTION WRITTEN
Friday, September 11, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 11, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, September 11, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, March 16, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, March 16, 2020NON-FINAL ACTION E-MAILED
Monday, March 16, 2020NON-FINAL ACTION WRITTEN
Monday, March 16, 2020ASSIGNED TO EXAMINER
Wednesday, February 26, 2020NOTICE OF DESIGN SEARCH CODE E-MAILED
Tuesday, February 25, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, February 25, 2020NEW APPLICATION ENTERED

Related Keywords

relatlimab nivolumab opdualag health antibodies care pharmaceutical information monoclonal providing preparations foregoing pharmaceuticals